REDWOOD CITY, California, May 5 /PRNewswire/ --

Ingenuity Systems, the leading provider of information solutions for life
science researchers, today announced a multi-year agreement with AstraZeneca.
AstraZeneca plans to expand the utilization of IPA in its research and target
discovery programs to gain deeper domain knowledge of disease-related
pathways and targets.

As part of the agreement, AstraZeneca researchers plan to leverage the
powerful analysis application, to build biological models, analyze data, and
reliably answer sophisticated biological and chemical questions in their
effort to identify and progress promising targets.

Results generated in IPA can be easily shared across teams, so
researchers can work together to make more informed decisions. "IPA is an
extensive platform for understanding and communicating the dynamic behaviors
of complex biological systems," said Dr Ian Dix, Principal Informatics
Scientist, AstraZeneca. "IPA can support a wide range of research objectives
across our target and biomarker discovery programs - such as providing
insight into target efficacy, drugability and, increasingly, toxicity. The
richness and contextual nature of the content is important for us because it
provides a detailed view of the molecular basis of disease, critical in the
drug discovery decision-making process."

"We are pleased to enhance and extend our relationship with AstraZeneca
and to continue to provide AstraZeneca's researchers with greater workflow
and decision support," said Sean Scott, SVP of Sales and Operations at
Ingenuity Systems. "IPA continues to deliver value to AstraZeneca researchers
by providing the right capabilities and content to understand biological
systems and uncover insights that impact business decisions."

About Ingenuity Pathways Analysis

Ingenuity Pathways Analysis (IPA) is an all-in-one software application
that enables researchers to model, analyze, and understand the complex
biological and chemical systems at the core of life science research. IPA's
search capabilities provide users with access to the highest quality
detail-rich knowledge available on genes, drugs, chemicals, protein families,
cellular and disease processes, and signaling and metabolic pathways. IPA
supports analysis of data from all experimental platforms, and is used at all
stages of the drug discovery and development process, including target
identification and validation, biomarker discovery, molecular toxicology,
metabolomics, and pharmacogenomics. IPA has been broadly adopted and cited in
hundreds of peer-reviewed journals.

About Ingenuity Systems(R)

Ingenuity Systems is a leading provider of information solutions and
custom services for life science researchers, computational biologists and
bioinformaticists, and life science industry suppliers. Our long-term focus
on innovation in semantic search has allowed us to create groundbreaking
technologies that have one common goal - to generate maximum value from all
types of biological and chemical knowledge. Ingenuity offerings leverage the
Ingenuity Knowledge Base, which contains uniquely structured literature
findings that allow scientists to ask complex biological questions and gain
rapid insight into their experimental data or systems of interest. Today,
Ingenuity's solutions are used by thousands of researchers at hundreds of
leading pharmaceutical, biotechnology, academic, and government research
institutions worldwide. For more information visit: www.ingenuity.com

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in
research, development, manufacturing and marketing of meaningful prescription
medicines and supplier for healthcare services. AstraZeneca is one of the
world's leading pharmaceutical companies with healthcare sales of US$ 31.6
billion and is a leader in gastrointestinal, cardiovascular, neuroscience,
respiratory, oncology and infectious disease medicines. For more information
visit: www.astrazeneca.com